Johnson & Johnson (NYSE:JNJ) has agreed to acquire Momenta Pharmaceuticals (NASDAQ:MNTA) for $52.50 per share in cash for a total of $6.5B.
The transaction should close in H2.
Momenta develops therapies for rare immune-mediated disorders leveraging its Fc Multimerization Platform. Lead candidate is nipocalimab, in Phase 3 development for warm autoimmune hemolytic anemia and Phase 2 for hemolytic disease of fetus and newborn and myasthenia gravis.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2025 citybuzz
